You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 16, 2024

Viiv Hlthcare Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Viiv Hlthcare
International Patents:514
US Patents:12
Tradenames:19
Ingredients:17
NDAs:26

Drugs and US Patents for Viiv Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare TIVICAY dolutegravir sodium TABLET;ORAL 204790-002 Jun 9, 2016 DISCN Yes No 8,129,385*PED ⤷  Try a Trial Y ⤷  Try a Trial
Viiv Hlthcare TIVICAY dolutegravir sodium TABLET;ORAL 204790-001 Aug 12, 2013 RX Yes Yes 8,129,385*PED ⤷  Try a Trial Y ⤷  Try a Trial
Viiv Hlthcare EPZICOM abacavir sulfate; lamivudine TABLET;ORAL 021652-001 Aug 2, 2004 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial
Viiv Hlthcare TIVICAY dolutegravir sodium TABLET;ORAL 204790-002 Jun 9, 2016 DISCN Yes No 9,242,986*PED ⤷  Try a Trial Y ⤷  Try a Trial
Viiv Hlthcare CABENUVA KIT cabotegravir; rilpivirine SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 212888-001 Jan 21, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial
Viiv Hlthcare CABENUVA KIT cabotegravir; rilpivirine SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 212888-001 Jan 21, 2021 RX Yes Yes 8,410,103 ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Viiv Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-002 Jul 14, 1999 5,563,142 ⤷  Try a Trial
Viiv Hlthcare RETROVIR zidovudine CAPSULE;ORAL 019655-001 Mar 19, 1987 4,828,838 ⤷  Try a Trial
Viiv Hlthcare RETROVIR zidovudine CAPSULE;ORAL 019655-001 Mar 19, 1987 4,833,130 ⤷  Try a Trial
Viiv Hlthcare RETROVIR zidovudine SOLUTION;ORAL 019910-001 Sep 28, 1989 4,833,130 ⤷  Try a Trial
Viiv Hlthcare EPIVIR lamivudine TABLET;ORAL 020564-003 Jun 24, 2002 5,905,082*PED ⤷  Try a Trial
Viiv Hlthcare TRIZIVIR abacavir sulfate; lamivudine; zidovudine TABLET;ORAL 021205-001 Nov 14, 2000 4,837,208 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for VIIV HLTHCARE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Oral Solution 10 mg/mL ➤ Subscribe 2011-11-22
➤ Subscribe Tablets 300 mg ➤ Subscribe 2009-01-28
➤ Subscribe Tablets 700 mg ➤ Subscribe 2012-01-18
➤ Subscribe Tablets 600 mg/300 mg ➤ Subscribe 2007-09-27
➤ Subscribe Tablets 600 mg/50 mg/300 mg ➤ Subscribe 2017-08-14
➤ Subscribe Tablets 150 mg and 300 mg ➤ Subscribe 2007-10-16
➤ Subscribe Tablets 150 mg and 300 mg ➤ Subscribe 2011-08-08
➤ Subscribe Oral Solution 20 mg/ml ➤ Subscribe 2012-12-27
➤ Subscribe Tablets 150 mg/300 mg ➤ Subscribe 2007-06-26
➤ Subscribe Tablets 10 mg, 25 mg and 50 mg ➤ Subscribe 2017-08-14
➤ Subscribe Tablets 300 mg/150 mg/300 mg ➤ Subscribe 2011-03-22

Supplementary Protection Certificates for Viiv Hlthcare Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1419152 132012902054377 Italy ⤷  Try a Trial PRODUCT NAME: EMTRICITABINA/RILPIVIRINA CLORIDRATO/TENOFOVIR DISOPROXIL FUMARATO(EVIPLERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/737/001-002, 20111128
1874117 14C0041 France ⤷  Try a Trial PRODUCT NAME: DOLUTEGRAVIR ET SES SELS OU SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES,NOTAMMENT LE DOLUTEGRAVIR SODIQUE.; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
1663240 92853 Luxembourg ⤷  Try a Trial PRODUCT NAME: COMBINAISON DE RILPIVIRINE OU UNE FORME THERAPEUTIQUE EQUIVALENTE QUI EN DERIVE TELLE QUE PROTEGEE PAR LE BREVET DE BASE, TEL QU'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE RILPIVIRINE, INCLUANT LE SEL CHLORHYDRATE DE RILPIVIRINE ET L'EMTRICITABINE
1874117 2014C/038 Belgium ⤷  Try a Trial PRODUCT NAME: DOULUTEGRAVIR SODIQUE; AUTHORISATION NUMBER AND DATE: EU/1/13/892 20140121
0434450 33/1999 Austria ⤷  Try a Trial PRODUCT NAME: ''ABACAVIR'', GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER DERIVATS, EINSCHLIESSLICH ABACAVIR-SULFAT.; NAT. REGISTRATION NO/DATE: EU/1/99/112/001 EU/1/99/112/002 19990708; FIRST REGISTRATION: LI 55048 001, 55049 002 19990628
1874117 2023C/545 Belgium ⤷  Try a Trial PRODUCT NAME: DOULUTEGRAVIR SODIQUE; AUTHORISATION NUMBER AND DATE: EU/1/13/892 20140121
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.